Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - Sarcomas- Cancers of the bones and soft body tissues

Jumbo Large Regular Text:

Adult Clinical Trials - Sarcomas- Cancers of the bones and soft body tissues

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Carolyn Andrews, RN or Ann-Marie Peters, RN at 919-681-4768 or fax 919-684-8926. For information about radiation or hyperthermia trials, please contact Madeline Carroll, RN at 919-668-3726.

Items 1 - 9 of 9

ARST08P1 A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
Principal Investigator: Susan Kreissman
Phase: N/A
Phone: 919-684-3401

ARST0921 A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
Principal Investigator: Susan Kreissman
Phase: Phase II
Phone: 919-684-3401

AEWS1031 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401

A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)
Principal Investigator: Elizabeth Reddy
Phase: Phase III
Phone: +255759060750

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Principal Investigator: Richard Riedel
Phase: Phase II
Phone: 919-668-3726

A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 year Adjuvant Imatinib Mesylate (Gleevec) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Principal Investigator: Richard Riedel
Phase: Phase II
Phone: 919-681-4768

An Open-Label, Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of AT13387, either as Monotherapy or in Combination with Imatinib, in Patients with Unresectable and/or Metastatic Malignant GIST whose Tumor has Progressed following Treatment with a Maximum of Three Tyrosine Kinase Inhibitors
Principal Investigator: Richard Riedel
Phase: Phase II
Phone: 919-681-4768

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Principal Investigator: Richard Riedel
Phase: Phase III

A Randomized, Open-label, Multi-center, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma
Principal Investigator: Richard Riedel
Phase: Phase III
Phone: 919-668-3726